Decision Resources, Inc., announces a new report, Next-Generation Metabolic Disease Therapeutics: An Analysis of Eight Therapeutic Pipelines for Diabetes and Obesity that analyzes the opportunities and hurdles awaiting new drugs in the metabolic disease marketplace.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Several drugs -- most notably those from a new class of drugs called thiazolidinediones (SmithKline Beecham's Avandia and Eli Lilly/Takeda's Actos) to treat insulin resistance in type 2 diabetes patients, and two new antiobesity drugs (Knoll Pharmaceuticals' Meridia and Roche's Xenical) -- are breakthrough products that offer important new options in addressing these often difficult-to-treat diseases. Nevertheless, the pharmaceutical industry and the medical community have a long way to go to address the unmet medical needs in metabolic diseases. The most glaring deficit in treating metabolic diseases is the lack of specific drugs for diabetic complications. Current antiobesity drugs have limited efficacy, and current drugs for type 2 diabetes-even in combination therapies-fail to fully normalize blood glucose in a majority of patients.

Next-Generation Metabolic Disease Therapeutics examines the current state of drug discovery and development pipelines in diabetes (including types 1 and 2 diabetes and diabetic complications) and obesity. The development pipelines in metabolic diseases of eight selected biopharmaceutical companies are examined, including deals between these companies and large pharmaceutical companies. The companies profiled are Alteon Pharmaceuticals, Amgen, Amylin Pharmaceuticals, Ligand Pharmaceuticals, Metabolex, Millennium Pharmaceuticals, Trega Biosciences, and Tularik. All have major programs in metabolic diseases, and in some cases, they specialize solely in this disease area.

Next-Generation Metabolic Disease Therapeutics: An Analysis of Eight Therapeutic Pipelines for Diabetes and Obesity is available for $5,000.00. Contact: Cindy Ohlman, 781.296.2521 (telephone), 781.296.2525 (fax), or ohlman@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, Inc., 781-296-2521, or
ohlman@dresources.com

Decision Resources Study Forecasts Growth in the Anxiety Disorders Drug Market

View Now